NCT01866098View on ClinicalTrials.gov

Naltrexone for Antipsychotic-Induced Weight Gain

NACompletedINTERVENTIONAL
Enrollment

144

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

April 7, 2019

Study Completion Date

April 7, 2019

Conditions
SchizophreniaSchizoaffective DisorderSchizophreniform DisorderBipolar DisorderSevere Major Depression With Psychotic Features
Interventions
DRUG

Naltrexone

25 or 50mg (randomized) oral capsule taken once daily for 52 weeks to establish optimal dose for weight loss over the course of the study.

DRUG

Placebo

Trial Locations (1)

06519

Connecticut Mental Health Center, New Haven

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Yale University

OTHER

NCT01866098 - Naltrexone for Antipsychotic-Induced Weight Gain | Biotech Hunter | Biotech Hunter